Clarithromycin 500 mg
Clarithromycin 500mg — same mechanism as RITHCLAR™ 250 (macrolide, 50S ribosomal binding, translocation inhibition). The 500mg dose is required for moderate-to-severe infections, H. pylori eradication regimens, and MAC prophylaxis and treatment where standard guidelines specify the higher dose. See RITHCLAR™ 250 for full mechanism detail.
Moderate-to-severe community-acquired pneumonia (combination with beta-lactam), H. pylori eradication (500mg + amoxycillin 1g + PPI twice daily for 14 days), Mycobacterium avium complex prophylaxis (500mg twice daily in HIV patients CD4 <50), severe acute exacerbations of chronic bronchitis, and complicated skin infections where higher macrolide concentrations are needed.
Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.
RITHCLAR™ 500 completes the clarithromycin range alongside RITHCLAR™ 250. The 500mg dose is non-negotiable for H. pylori eradication — studies consistently show that 250mg-based triple therapy achieves lower eradication rates than 500mg regimens. Having both strengths under a single brand ensures prescribers can select the appropriate dose for each indication while remaining within the Seclis Labs portfolio.
Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.